The prognosis of human epidermal growth factor receptor 2 (HER2)-positive breast cancer has improved dramatically with the advent of HER2-targeted therapy; however, the prognosis for patients with brain metastases (BMs) remains poor. This evidence concerns the gene ERBB2 and breast carcinoma.